ADMA
ADMA Biologics, Inc. [ADMA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ADMA Stock Summary
Top 10 Correlated ETFs
ADMA
Top 10 Correlated Stocks
ADMA
In the News
ADMA Financial details
Company Rating
Neutral
Market Cap
1.37B
Income
-34.21M
Revenue
258.22M
Book val./share
0.6
Cash/share
0.23
Dividend
-
Dividend %
-
Employees
624
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-26.87
Forward P/E
-
PEG
4.17
P/S
4.89
P/B
7.54
P/C
27.09
P/FCF
-48.76
Quick Ratio
2.52
Current Ratio
6.54
Debt / Equity
0.97
LT Debt / Equity
0.97
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
-
EPS this Y
-69.77%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-34.15%
Revenue last 5Y
54.48%
Revenue Q/Q
9.85%
EPS Q/Q
-785.09%
-
-
-
-
SMA20
-
SMA50
20%
SMA100
50%
Inst Own
62.37%
Inst Trans
0.84%
ROA
-12%
ROE
-29%
ROC
-
Gross Margin
31%
Oper. Margin
1%
Profit Margin
-18%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.06-6.76
52W High
+3.83%
52W Low
+107.67%
RSI
54
Rel Volume
0.95
Avg Volume
2.57M
Volume
2.45M
Perf Week
0.16%
Perf Month
-1.74%
Perf Quarter
88.22%
Perf Half Y
81.1%
-
-
-
-
Beta
0.428
-
-
Volatility
0.09%, 0.19%
Prev Close
0.48%
Price
6.23
Change
3.32%
ADMA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.54 | 0.49 | 0.58 | 0.78 | 1.15 | |
| Net income per share | -1.05 | -1.02 | -0.61 | -0.43 | -0.13 | |
| Operating cash flow per share | -1.4 | -1.18 | -0.81 | -0.3 | 0.04 | |
| Free cash flow per share | -1.47 | -1.33 | -0.9 | -0.37 | 0.02 | |
| Cash per share | 0.49 | 0.65 | 0.37 | 0.44 | 0.23 | |
| Book value per share | 0.48 | 1.02 | 1.01 | 0.77 | 0.6 | |
| Tangible book value per share | 0.36 | 0.96 | 0.97 | 0.75 | 0.59 | |
| Share holders equity per share | 0.48 | 1.02 | 1.01 | 0.77 | 0.6 | |
| Interest debt per share | 1.72 | 1.27 | 0.83 | 0.88 | 0.7 | |
| Market cap | 217.39M | 167.98M | 196.81M | 767.75M | 1.01B | |
| Enterprise value | 275.37M | 209.73M | 248.64M | 835.68M | 1.1B | |
| P/E ratio | -3.81 | -1.92 | -2.33 | -9.01 | -35.85 | |
| Price to sales ratio | 7.41 | 3.98 | 2.43 | 4.98 | 3.92 | |
| POCF ratio | -2.85 | -1.65 | -1.75 | -12.9 | 115.04 | |
| PFCF ratio | -2.72 | -1.46 | -1.56 | -10.46 | 265.09 | |
| P/B Ratio | 8.3 | 1.9 | 1.39 | 5.05 | 7.49 | |
| PTB ratio | 8.3 | 1.9 | 1.39 | 5.05 | 7.49 | |
| EV to sales | 9.38 | 4.97 | 3.07 | 5.42 | 4.27 | |
| Enterprise value over EBITDA | -6.88 | -3.27 | -4.3 | -21.3 | 36.79 | |
| EV to operating cash flow | -3.61 | -2.06 | -2.21 | -14.04 | 125.28 | |
| EV to free cash flow | -3.44 | -1.83 | -1.98 | -11.38 | 288.67 | |
| Earnings yield | -0.26 | -0.52 | -0.43 | -0.11 | -0.03 | |
| Free cash flow yield | -0.37 | -0.68 | -0.64 | -0.1 | 0 | |
| Debt to equity | 3.23 | 1.11 | 0.73 | 1.02 | 0.97 | |
| Debt to assets | 0.67 | 0.47 | 0.37 | 0.44 | 0.4 | |
| Net debt to EBITDA | -1.45 | -0.65 | -0.9 | -1.73 | 3.01 | |
| Current ratio | 6.12 | 7.71 | 6.87 | 6.89 | 5.16 | |
| Interest coverage | -4.61 | -5.42 | -4.47 | -2.04 | 0.86 | |
| Income quality | 1.58 | 1.35 | 1.57 | 0.9 | -0.31 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | -0.03 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.08 | 0.14 | 0.05 | 0.02 | 0.01 | |
| Intangibles to total assets | 0.05 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.05 | 0.12 | 0.12 | 0.23 | -0.57 | |
| Capex to revenue | -0.13 | -0.3 | -0.17 | -0.09 | -0.02 | |
| Capex to depreciation | -1.17 | -3.23 | -2.46 | -1.96 | -0.6 | |
| Stock based compensation to revenue | 0.09 | 0.07 | 0.04 | 0.03 | 0.02 | |
| Graham number | 3.37 | 4.84 | 3.71 | 2.73 | 1.31 | |
| ROIC | -0.44 | -0.39 | -0.27 | -0.16 | 0.08 | |
| Return on tangible assets | -0.47 | -0.43 | -0.31 | -0.25 | -0.09 | |
| Graham Net | -0.83 | -0.15 | 0 | -0.08 | -0.16 | |
| Working capital | 71.79M | 133.79M | 178.35M | 231.13M | 207.21M | |
| Tangible asset value | 19.5M | 82.28M | 135.91M | 147.43M | 131.18M | |
| Net current asset value | -15.08M | 34.32M | 73.65M | 73.91M | 63.04M | |
| Invested capital | 3.23 | 1.11 | 0.73 | 1.02 | 0.97 | |
| Average receivables | 2.43M | 8.35M | 20.91M | 22.04M | 21.46M | |
| Average payables | 7.54M | 10.12M | 11.75M | 12.83M | 14.44M | |
| Average inventory | 35.84M | 67.3M | 103.13M | 144M | 168.09M | |
| Days sales outstanding | 43.15 | 114.44 | 128.86 | 36.73 | 38.76 | |
| Days payables outstanding | 84.77 | 65.95 | 56.87 | 40.64 | 33.62 | |
| Days of inventory on hand | 490.29 | 485.56 | 570.7 | 501.6 | 371.25 | |
| Receivables turnover | 8.46 | 3.19 | 2.83 | 9.94 | 9.42 | |
| Payables turnover | 4.31 | 5.53 | 6.42 | 8.98 | 10.86 | |
| Inventory turnover | 0.74 | 0.75 | 0.64 | 0.73 | 0.98 | |
| ROE | -2.18 | -0.99 | -0.6 | -0.56 | -0.21 | |
| Capex per share | -0.07 | -0.15 | -0.1 | -0.07 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.25 | 0.26 | 0.27 | 0.3 | 0.33 | |
| Net income per share | -0.13 | -0.06 | -0.03 | 0.01 | -0.08 | |
| Operating cash flow per share | -0.04 | -0.07 | -0.03 | 0.05 | 0.08 | |
| Free cash flow per share | -0.05 | -0.08 | -0.03 | 0.05 | 0.07 | |
| Cash per share | 0.43 | 0.31 | 0.28 | 0.33 | 0.23 | |
| Book value per share | 0.75 | 0.66 | 0.66 | 0.67 | 0.6 | |
| Tangible book value per share | 0.73 | 0.64 | 0.64 | 0.65 | 0.58 | |
| Share holders equity per share | 0.75 | 0.66 | 0.66 | 0.67 | 0.6 | |
| Interest debt per share | 0.79 | 0.73 | 0.71 | 0.71 | 0.61 | |
| Market cap | 786.98M | 734.56M | 821.7M | 806.49M | 1.02B | |
| Enterprise value | 854.9M | 821.08M | 910.7M | 885.31M | 1.11B | |
| P/E ratio | -7.59 | -14.39 | -32.25 | 78.6 | -14.47 | |
| Price to sales ratio | 15.75 | 12.91 | 13.67 | 11.99 | 13.82 | |
| POCF ratio | -106.65 | -49.89 | -135.62 | 67.29 | 58.05 | |
| PFCF ratio | -70.72 | -44.07 | -118.55 | 71.83 | 63.09 | |
| P/B Ratio | 5.18 | 5.04 | 5.6 | 5.33 | 7.55 | |
| PTB ratio | 5.18 | 5.04 | 5.6 | 5.33 | 7.55 | |
| EV to sales | 17.1 | 14.43 | 15.15 | 13.16 | 15.04 | |
| Enterprise value over EBITDA | -135.36 | -1.66K | 449.51 | 80.08 | 68.01 | |
| EV to operating cash flow | -115.85 | -55.77 | -150.31 | 73.87 | 63.16 | |
| EV to free cash flow | -76.83 | -49.26 | -131.39 | 78.84 | 68.66 | |
| Earnings yield | -0.03 | -0.02 | -0.01 | 0 | -0.02 | |
| Free cash flow yield | -0.01 | -0.02 | -0.01 | 0.01 | 0.02 | |
| Debt to equity | 1.02 | 1.07 | 1.03 | 1.01 | 0.97 | |
| Debt to assets | 0.44 | 0.46 | 0.44 | 0.44 | 0.4 | |
| Net debt to EBITDA | -10.75 | -174.97 | 43.93 | 7.13 | 5.51 | |
| Current ratio | 6.89 | 7.19 | 6.35 | 6.54 | 5.16 | |
| Interest coverage | -1.06 | -0.13 | -0.08 | 1.36 | 2.29 | |
| Income quality | 0.6 | 2.17 | 0.95 | 4.67 | -1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.08 | 0 | -0.04 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.51 | 0.13 | 0.14 | -0.06 | -0.08 | |
| Capex to revenue | -0.07 | -0.03 | -0.01 | -0.01 | -0.02 | |
| Capex to depreciation | -1.94 | -0.96 | -0.42 | -0.36 | -0.67 | |
| Stock based compensation to revenue | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | |
| Graham number | 1.47 | 0.92 | 0.65 | 0.41 | 1.03 | |
| ROIC | -0.04 | 0 | 0 | -0.04 | 0.05 | |
| Return on tangible assets | -0.08 | -0.04 | -0.02 | 0.01 | -0.05 | |
| Graham Net | -0.08 | -0.11 | -0.11 | -0.08 | -0.16 | |
| Working capital | 231.13M | 227.36M | 224.29M | 231.86M | 207.21M | |
| Tangible asset value | 147.43M | 141.29M | 142.58M | 147.43M | 131.18M | |
| Net current asset value | 73.91M | 68.95M | 69.98M | 76.14M | 63.04M | |
| Invested capital | 1.02 | 1.07 | 1.03 | 1.01 | 0.97 | |
| Average receivables | 18.2M | 21.01M | 31.63M | 34.03M | 29.37M | |
| Average payables | 19.21M | 13.09M | 12.52M | 11.47M | 13.26M | |
| Average inventory | 163.1M | 163.63M | 162.88M | 162.45M | 168.01M | |
| Days sales outstanding | 27.92 | 41.93 | 54.98 | 41.9 | 33.39 | |
| Days payables outstanding | 33.25 | 28.86 | 25.04 | 22.91 | 32.77 | |
| Days of inventory on hand | 410.43 | 365.31 | 335.23 | 344.43 | 361.86 | |
| Receivables turnover | 3.22 | 2.15 | 1.64 | 2.15 | 2.7 | |
| Payables turnover | 2.71 | 3.12 | 3.59 | 3.93 | 2.75 | |
| Inventory turnover | 0.22 | 0.25 | 0.27 | 0.26 | 0.25 | |
| ROE | -0.17 | -0.09 | -0.04 | 0.02 | -0.13 | |
| Capex per share | -0.02 | -0.01 | 0 | 0 | -0.01 |
ADMA Frequently Asked Questions
What is ADMA Biologics, Inc. stock symbol ?
ADMA Biologics, Inc. is a US stock , located in Ramsey of Nj and trading under the symbol ADMA
What is ADMA Biologics, Inc. stock quote today ?
ADMA Biologics, Inc. stock price is $6.23 today.
Is ADMA Biologics, Inc. stock public?
Yes, ADMA Biologics, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.57M
- Market Capitalization 1.37B
- Employee 624
- CEO Mr. Adam S. Grossman
- Headquarters Ramsey,NJ,US
- IPO Date 2013-10-17
-
Website
https://www.admabiologics.com 
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
